Therapeutic agents to reduce HMB in WBD
| Agent . | Mechanism of action . | Route . | Complications . |
|---|---|---|---|
| COC | Synthesis of clotting factor | Oral | Headache, hypertension. |
| Levonorgestrel IUD (Mirena) | Local hormonal effect | Intrauterine | Dislodged by clots, weight gain, depression. |
| Tranexamic acid (Lysteda) | Local antifibrinolytic effect | Oral | Nausea, frequent dosing. |
| Desmopressin (DDAVP) Stimate (DDAVP) | Promotes release of endothelial VWF | IV Intranasal | Headache, flushing, allergic reaction, hyponatremia, tachyphylaxis. |
| rVWF pdVWF | Replaces deficient or defective VWF | IV | Invasive by IV route, costly. |
| Agent . | Mechanism of action . | Route . | Complications . |
|---|---|---|---|
| COC | Synthesis of clotting factor | Oral | Headache, hypertension. |
| Levonorgestrel IUD (Mirena) | Local hormonal effect | Intrauterine | Dislodged by clots, weight gain, depression. |
| Tranexamic acid (Lysteda) | Local antifibrinolytic effect | Oral | Nausea, frequent dosing. |
| Desmopressin (DDAVP) Stimate (DDAVP) | Promotes release of endothelial VWF | IV Intranasal | Headache, flushing, allergic reaction, hyponatremia, tachyphylaxis. |
| rVWF pdVWF | Replaces deficient or defective VWF | IV | Invasive by IV route, costly. |
IUD, intrauterine device.